18 résultats avec le mot-clé: 'cytoplasmic signalling abl tyrosine kinase normal cancer cells'
In breast cancer cells, c-Abl phosphorylation is induced by plasma membrane tyrosine kinases including SFK, EGFR family members and Insulin Growth factor I Receptor
N/A
Additional information can be conveyed along with the event, such as the identifier of the network attachment point (e.g., IEEE 802.11 Basic Service Set Identification (BSSID)
N/A
Keywords: Prostate cancer (PCa), Suppressor of Cytokine Signalling 1 (SOCS1), hepatocyte growth factor (HGF) receptor tyrosine kinase
N/A
In Vitro Effects of BCR-ABL Tyrosine Kinase Inhibitors on Endothelial Cells Survival and Functions.. Haguet, Hélène; Douxfils, Jonathan; Chatelain, Christian; GRAUX, Carlos;
N/A
Here, we review how the Src-like adaptor protein (SLAP) and the suppressor of cytokine signalling (SOCS) adaptor proteins regulate the SRC and the Janus kinase (JAK) oncogenic
N/A
ERK5 activity of cells were treated with 5 µM SU6656, 10 µM Imatinib or vehicle (DMSO) Autophosphorylated ERK5 ( 32 P-ERK5), phosphorylation of MEF2C ( 32 P-MEF2C), levels of
N/A
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid
N/A
BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of
N/A
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib STI571 in chronic phase and blast crisis chronic myeloid
N/A
Somatic mutations of EGFR at tyrosine kinase domain have been associated with clinical response to tyrosine kinase inhibitors (TKIs) in lung cancer patients.. In this study,
N/A
PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner.. Regulation
N/A
We demonstrate here that in cancer cells harboring met gene amplification, inhibition of Met activity with tyrosine kinase inhibitors or specific siRNA drastically decreased
N/A
Technique de photo-inscription de guide d’onde par laser `a impulsion ultra-br `eve.. Apparue il y a plus de
N/A
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia-chromosome positive chronic myelogenous
N/A
EGFR tyrosine kinase is regarded as an important target to search the effective pharmacological compounds that can inhibit the growth of cancer cells, since the majority of
N/A
Cette réactivation est secondaire à l’ampli- fication du gène BCR-ABL chez trois patients et à une mutation ponc- tuelle dans le domaine tyrosine kinase du gène BCR-ABL chez
N/A
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia
N/A
Abstract: Chronic myeloid leukemia (CML) is a clonal myeloproliferative malignancy initiated by tyrosine kinase activity of the fusion oncoprotein BCR-ABL in very
N/A